Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
This study investigated whether a self-assembling Growth Hormone-Releasing Peptide-6 (GHRP-6) peptide hydrogel could improve outcomes in acute kidney injury (AKI) by targeting metabolic reprogramming in renal tubular epithelial cells (TECs). Using a mouse model of AKI (likely ischemia-reperfusion injury), the researchers administered the GHRP-6 hydrogel and performed metabolomic sequencing analysis to characterize changes in cellular metabolism. The study found that treatment was associated with elevated levels of spermidine, L-glutamine, and acetyl-CoA — metabolites linked to amino acid and fatty acid metabolism — suggesting a favorable metabolic shift in TECs. Further mechanistic experiments indicated that the GHRP-6 hydrogel promoted TEC survival under ischemic conditions by activating the mTOR-P70 signaling pathway. The authors conclude that GHRP-6 hydrogel may protect TECs and reduce the risk of post-AKI fibrosis through metabolic reprogramming. Key limitations include that findings are restricted to a mouse model with no human data, the sample sizes and controls are not detailed in the abstract, and translation to clinical settings remains undemonstrated. The novel hydrogel formulation adds a materials-science dimension but also introduces additional variables requiring further study.
Why this grade: All experimental findings were generated in a mouse AKI model with no human subjects or clinical data reported, limiting direct translation of conclusions to humans.
Renal tubular epithelial cells (TECs), which are highly susceptible to injury during acute kidney injury (AKI), have notable regenerative effects on renal recovery after AKI. AKI-driven metabolic reprogramming of TECs plays a critical role in determining whether kidneys recover functionally or develop fibrosis. Targeting the metabolism of TECs offers valuable insights into AKI treatment. Growth hormone-releasing hormone (GHRH) and its analog GHRH peptide (GHRP) play beneficial roles in the field of regenerative medicine. Here, we designed a self-assembling GHRP-6 peptide hydrogel, and we hypothesized that this hydrogel could reprogram the metabolism of TECs, further enhancing recovery from AKI. Metabolomic sequencing analysis revealed that spermidine, L-glutamine, and acetyl-CoA, which are involved in amino acid and fatty acid metabolism, were highly enriched in a mouse model of AKI treated with the GHRP-6 hydrogel. Further study revealed that GHRP-6 hydrogel treatment enhanced the survival of TECs in the ischemic microenvironment by activating the mTOR-P70 pathway. In conclusion, GHRP-6 hydrogel treatment has beneficial therapeutic effects on AKI through the targeting of metabolic reprogramming, which offers a novel therapeutic strategy to protect TECs in AKI treatment.
Educational summary of published research — not medical advice. License: cc by-nc-nd. Full text is shown only where licensing permits.